Haider Syed Muhammad Safi, Alvi Shaf Ali, Khan Hamza, Majeed Rameen, Syed Tatheer, Anwar Adnan, Hashmi Atif A
Internal Medicine, Hamdard College of Medicine and Dentistry, Karachi, PAK.
General Surgery, Hamdard College of Medicine and Dentistry, Karachi, PAK.
Cureus. 2023 Jun 23;15(6):e40878. doi: 10.7759/cureus.40878. eCollection 2023 Jun.
Introduction The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) epidemic spread quickly. Vaccines are now being distributed to stop the infectious spread and halt fatalities. The Pfizer-BioNTech vaccine was the first mRNA-based vaccine introduced to boost immunity against COVID-19; however, it could lead to various adverse reactions. Therefore, the aim of this study was to assess the prevalence of Pfizer vaccine side effects among participants. Methods This was a multicenter cross-sectional study that was performed using a non-probability sampling method. The study period was about six months from March 1, 2022, to August 31, 2022. A total of 1000 participants who received two doses of the Pfizer vaccine met the inclusion criteria. Demographic details of participants, for example, gender, age, comorbidities, Pfizer vaccine with both doses along with booster dose, previous exposure to coronavirus disease 2019 (COVID-19) infection, and the incidence of any local and systemic side effects following the first and second doses of vaccine, were reported. Results The study findings showed that out of 1000 participants, 644 (64.4%) were males and 356 (35.6%) were females; their mean age was 43.06±14.98 years. Among them, 280 (28.0%) had hypertension and 356 (35.6%) had diabetes. Following the first dose of the Pfizer vaccine, burning at the injection site and fever were the most commonly reported side effects in 704 (70.4%) and 700 (70.0%) participants, respectively. Following the second dose of the Pfizer vaccine, muscle pain was the most commonly reported side effect in 628 (62.8%) participants. Conclusion This study concluded that the most frequent adverse effects of the Pfizer vaccine were burning at the injection site, fever, pain at the injection site, muscle pain, swelling at the injection site, and joint pain. Moreover, the first dose was associated with more side effects than the second dose.
引言 严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情迅速蔓延。目前正在分发疫苗以阻止感染传播并减少死亡。辉瑞-BioNTech疫苗是第一种引入的基于mRNA的疫苗，用于增强对2019冠状病毒病（COVID-19）的免疫力；然而，它可能导致各种不良反应。因此，本研究的目的是评估参与者中辉瑞疫苗副作用的发生率。方法 这是一项多中心横断面研究，采用非概率抽样方法进行。研究期约为6个月，从2022年3月1日至2022年8月31日。共有1000名接受两剂辉瑞疫苗的参与者符合纳入标准。报告了参与者的人口统计学细节，例如性别、年龄、合并症、两剂辉瑞疫苗以及加强剂量、既往接触2019冠状病毒病（COVID-19）感染情况，以及第一剂和第二剂疫苗接种后任何局部和全身副作用的发生率。结果 研究结果显示，在1000名参与者中，644名（64.4%）为男性，356名（35.6%）为女性；他们的平均年龄为43.06±14.98岁。其中，280名（28.0%）患有高血压，356名（35.6%）患有糖尿病。在接种第一剂辉瑞疫苗后，注射部位烧灼感和发热是最常报告的副作用，分别有704名（70.4%）和700名（70.0%）参与者出现。在接种第二剂辉瑞疫苗后，肌肉疼痛是最常报告的副作用，有628名（62.8%）参与者出现。结论 本研究得出结论，辉瑞疫苗最常见的不良反应是注射部位烧灼感、发热、注射部位疼痛、肌肉疼痛、注射部位肿胀和关节疼痛。此外，第一剂疫苗比第二剂疫苗的副作用更多。
